Thrombotic Thrombocytopenic Purpura (TTP)

This is a serious condition where blood clots form in small blood vessels. This causes a low platelet count and red blood cell destruction. It can be inherited or acquired. It can lead to kidney failure and other serious problems.

Condition

What people with Thrombotic Thrombocytopenic Purpura (TTP) report

Every report comes from a Lived member, sent anonymously.

Have you had Plasma Exchange for Thrombotic Thrombocytopenic Purpura (TTP)?

NameHow it went

About Thrombotic Thrombocytopenic Purpura (TTP)

What It Is

Thrombotic thrombocytopenic purpura (TTP) is a rare, life-threatening blood disorder in which tiny clots form in small blood vessels throughout the body. These clots can reduce blood flow to the brain, kidneys, heart and gut, which is what makes TTP dangerous. Because the clots use up platelets (the blood cells that normally help seal cuts), people can also bruise or bleed easily. The name describes the main features: thrombotic refers to the clots, thrombocytopenic means a low platelet count, and purpura are the purple bruise-like spots that appear when blood leaks under the skin. Red blood cells are also torn apart as they squeeze past the clots, causing a type of anemia. TTP usually comes on suddenly, often over days, and needs treatment in hospital right away.

Causes & Risk Factors

TTP happens when the body lacks enough working ADAMTS13, an enzyme that keeps a clotting protein called von Willebrand factor in check. Without it, platelets clump together inside small vessels. There are two main forms. Acquired, or immune, TTP accounts for more than 95% of cases: the immune system makes antibodies that block ADAMTS13. It mostly affects adults and occurs more often in women and in Black Americans. Infections, pregnancy, lupus, cancer, stem cell transplant and some medicines (including the blood thinners clopidogrel and ticlopidine, the transplant drug cyclosporine, some chemotherapy and quinine) have been linked to it, although often no trigger is found. Congenital TTP, also called Upshaw-Schulman syndrome, is inherited. A person receives a faulty ADAMTS13 gene from each parent, who usually have no symptoms themselves. It often appears in newborns or children, but some people are not diagnosed until adulthood, sometimes during a first pregnancy.

How It's Diagnosed

TTP is suspected when someone has a low platelet count together with signs that red blood cells are being broken apart, often with confusion, headache, kidney changes or abdominal symptoms. A blood smear viewed under a microscope shows torn red cell fragments. Other blood tests, including bilirubin and lactate dehydrogenase (LDH), rise as red cells break down, and kidney and urine tests show whether the kidneys are affected. The key test measures ADAMTS13 activity. A level below 10% of normal is the hallmark of TTP and separates it from look-alike conditions such as hemolytic uremic syndrome, which is treated differently. A test for antibodies against ADAMTS13 points to the acquired form, and genetic testing can confirm the congenital form. Because ADAMTS13 results can take time, doctors often start treatment based on the overall picture before the result returns.

Treatment Options

TTP is a medical emergency, and treatment begins in hospital as soon as it is suspected. For acquired TTP, the core treatment is therapeutic plasma exchange: a machine removes the person's plasma (the liquid part of the blood), which carries the harmful antibodies, and replaces it with donor plasma containing working ADAMTS13. It is usually repeated daily until the platelet count recovers and red cell damage stops. Medicines that calm the immune system are given alongside it, usually corticosteroids such as prednisone and often rituximab, an antibody drug that lowers the production of the antibodies against ADAMTS13. Caplacizumab (Cablivi), an injected antibody fragment that stops platelets from clumping, can be added for adults and children 12 and older. It helps control the clotting faster, but it raises the risk of bleeding while it is being used. Congenital TTP is treated by replacing the missing enzyme. Recombinant ADAMTS13 (Adzynma), a lab-made version given through a vein, is approved for both regular prevention and treating episodes, and guidelines now favor it where it is available. Donor plasma infusions remain an alternative. Decisions about ongoing prevention weigh the benefits against the burden of regular infusions.

What to Expect

With prompt treatment, most people recover from an acute episode, though the hospital stay usually lasts days to weeks. Some people still die of TTP, mainly when diagnosis is delayed, which is why fast treatment matters so much. TTP can come back. Relapses happen in both forms, so follow-up continues after recovery, with regular blood counts and ADAMTS13 testing. In acquired TTP, a falling ADAMTS13 level can signal a relapse before symptoms appear, and doctors may give rituximab at that point to head it off. People with congenital TTP may receive regular preventive enzyme or plasma infusions. Pregnancy needs particular planning, because it can trigger episodes in both forms. Some survivors notice lasting effects, including problems with memory or concentration, anxiety or depression, and a higher risk of high blood pressure and stroke. Telling the care team about these changes matters, since they can be checked and supported.

When to Seek Help

If you have had TTP, keep every scheduled blood test, and plan pregnancy, surgery or new medicines with your hematologist. Get a same-day blood count, by contacting your care team right away, if you notice new unexplained bruising, tiny red or purple spots on the skin, unusual bleeding, yellowing of the skin or eyes, blood in the urine or sudden extreme tiredness, whether or not you have had TTP before. Call 911 for sudden confusion, trouble speaking, weakness on one side of the body, a seizure or chest pain, since these can mean clots are affecting the brain or heart.

Questions to Ask Your Doctor

  1. 1.Is my TTP the acquired or the congenital form, and how does that change my treatment?
  2. 2.How often should my ADAMTS13 level be checked, and what result would make us act before symptoms appear?
  3. 3.What are the signs of a relapse, and who should I contact if I notice them?
  4. 4.Are there medicines, procedures or a pregnancy I should plan carefully because of TTP?
  5. 5.Should I be checked for longer-term effects such as memory problems, mood changes or high blood pressure?

Last reviewed • Oct 2026

Educational content, not medical advice.